Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also...
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...
Swiss CDMO Siegfried has acquired a 95% stake in Dinamiqs, a compatriot biotech focused on developing and manufacturing viral vectors for cell and gene therapies.
Austrian biotech Proxygen has announced a multi-year collaboration and license agreement with US drugmaker Merck & Co to identify and develop molecular glue degraders...
Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531...
Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in...
Solvay’s venture capital fund has joined the Genesis Consortium, a global alliance of venture capital firms and corporations that support startups leveraging...
A new venture capital vehicle launched by a group of biotech entrepreneurs is designed to act as a seed investor as well as a drug discovery co-pilot for biotech startups...
